BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 24492037)

  • 1. [Management strategy for BCR-ABL negative myeloproliferative neoplasms].
    Gotoh A; Komatsu N
    Rinsho Ketsueki; 2014 Jan; 55(1):56-65. PubMed ID: 24492037
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloproliferative neoplasms in the elderly.
    Maffioli M; Orlandi E; Passamonti F
    Eur J Intern Med; 2018 Dec; 58():33-42. PubMed ID: 29793825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloproliferative Neoplasms.
    Spivak JL
    N Engl J Med; 2017 Jun; 376(22):2168-2181. PubMed ID: 28564565
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.
    Macdonald D; Cross NC
    Pathobiology; 2007; 74(2):81-8. PubMed ID: 17587879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Michiels JJ; Pich A; De Raeve H; Gadisseur A
    Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
    [No Abstract]   [Full Text] [Related]  

  • 9. MPN blast phase: clinical challenge and assessing response.
    Mesa RA; Tibes R
    Leuk Res; 2012 Dec; 36(12):1496-7. PubMed ID: 22999527
    [No Abstract]   [Full Text] [Related]  

  • 10. Myeloproliferative neoplasms.
    Publicover A; Medd P
    Clin Med (Lond); 2013 Apr; 13(2):188-92. PubMed ID: 23681871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Searching for CALRity in myeloproliferative neoplasms.
    Cook JR
    Am J Clin Pathol; 2015 May; 143(5):617-9. PubMed ID: 25873492
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantification of JAK2V617F mutation by next-generation sequencing technology.
    Abdelhamid E; Figeac M; Renneville A; Quief S; Villenet C; Boyer T; Nibourel O; Coiteux V; Cassinat B; Lippert E; Helevaut N; Soua Z; Preudhomme C
    Am J Hematol; 2013 Jun; 88(6):536-7. PubMed ID: 23553621
    [No Abstract]   [Full Text] [Related]  

  • 13. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic evaluation of myeloproliferative neoplasms.
    Azzato EM; Bagg A
    Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment strategy for myeloproliferative neoplasms].
    Yoshimoto G; Miyamoto T
    Rinsho Ketsueki; 2014 Oct; 55(10):1841-52. PubMed ID: 25297748
    [No Abstract]   [Full Text] [Related]  

  • 16. Myeloproliferative neoplasms: new translational therapies.
    Mascarenhas J; Hoffman R
    Mt Sinai J Med; 2010; 77(6):667-83. PubMed ID: 21105128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
    Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of myeloproliferative neoplasms other than chronic leukemia].
    Ohyashiki JH
    Nihon Rinsho; 2009 Oct; 67(10):1964-8. PubMed ID: 19860198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.
    Plo I; Vainchenker W
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S329-39. PubMed ID: 19778861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).
    Reilly JT
    Leukemia; 2008 Oct; 22(10):1818-27. PubMed ID: 18754027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.